Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Neoleukin Therapeutics Inc | NLTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.49 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 3.05 - 4.70 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 3.49 | USD |
Neoleukin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
40.7M | 11.66M | - | 0 | -36.32M | -3.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Neoleukin Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
6/18/2024 | 13:11 | Edgar (US Regulatory) | Form 8-K - Current report |
6/17/2024 | 13:37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
6/17/2024 | 13:37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
6/17/2024 | 13:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
6/17/2024 | 13:35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
6/17/2024 | 13:35 | Edgar (US Regulatory) | Form 8-K - Current report |
6/03/2024 | 06:31 | Edgar (US Regulatory) | Form 8-K - Current report |
5/10/2024 | 15:14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/10/2024 | 06:31 | Edgar (US Regulatory) | Form 8-K - Current report |
5/07/2024 | 05:20 | Edgar (US Regulatory) | Form 8-K - Current report |
4/26/2024 | 13:34 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
4/26/2024 | 13:33 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NLTX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 3.80 | 4.70 | 3.05 | 3.58 | 162,757 | -0.31 | -8.16% |
3 Years | 51.00 | 52.80 | 1.875 | 10.55 | 239,855 | -47.51 | -93.16% |
5 Years | 19.90 | 90.65 | 1.875 | 33.53 | 271,777 | -16.41 | -82.46% |
Neoleukin Therapeutics Description
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |